Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. März 2025 07:30 ET | Quelle: Cybrexa Therapeutics

Cybrexa Therapeutics Announces New Preclinical Data on Tumor-Selective Peptide-Drug Conjugates at ESMO Targeted Anticancer Therapies Congress 2025

Cybrexa presented new data from its clinical-stage alphalex™ peptide-drug conjugate technology at ESMO Targeted Anticancer Therapies Congress 2025.
07. Oktober 2024 07:00 ET | Quelle: Cybrexa Therapeutics

Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer

Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
06. Februar 2024 08:00 ET | Quelle: Cybrexa Therapeutics

Cybrexa Regains Rights to CBX-12

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
10. September 2021 09:57 ET | Quelle: Cybrexa Therapeutics

Cybrexa Therapeutics to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference

NEW HAVEN, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...
04. August 2021 11:50 ET | Quelle: Cybrexa Therapeutics

Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021

NEW HAVEN, Conn., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug...